For me, today's efficacy data strengthens the Leronlimab
For me, today's efficacy data strengthens the Leronlimab story a great deal. There are folks like AF who say this molecule is a fake. But CYDY can't fake efficacy in an FDA double blind, placebo trial. Now, the drug has shown efficacy in HIV, cancer, and COVID (not to mention reported strong results in animal studies for NASH and MS).
It really took guts for a company like CYDY to entry the fray in the mild to moderate COVID population. Nobody knows ahead of time if the drug will work in a novel virus, and imagine the beating the company would take if it did not work. A management team trying to con investors would not do this. In contrast, this management team really believes in the potential of Leronlimab and are willing to put it out there for one indication after another. My hat's off to them.
In Top Gun verbiage, its almost like their egos are writing checks their bodies can't cash. But Leronlimab has consistently and safely delivered each time.
12
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Stepping Boldly into the Livestreaming Arena There's a new kid in the chaotic neighborhood of social media, and it's called GoLive Streamers. Not just another aimless stroll down Content Highway, GoLive is weaving its own defining path by fostering genuine real-time interaction. Launched in April 2026, this plucky platform has quickly amassed a following of over 74,000...
Continue Reading
Riding the Mobile Revolution with Grooming Anyone who's dabbled in grooming knows that moving to a mobile setup isn’t just about freedom and flexibility—it's a whole new ballgame. We're talking Chris Hanvey-level insights here, direct from Easley, S.C. This ain't your average jump in a van and snip some fur operation. Choosing the Right Rig First on the list: the...
Continue Reading
Straight outta Burlington, the M&T Bank Vermont City Marathon is giving its course a facelift and, get this, throwing a half marathon into the mix for 2027. It's about time they shook things up, considering how this race is supposed to be one of the most welcoming on the block. I mean, you're talking about a marathon that's practically been the crown jewel of Vermont's...
Continue Reading
Another Year, Another Milestone for Apex Dental Let's talk about steady growth. Apex Dental Partners has made it onto the Inc. 5000 list for the eighth straight year, landing at No. 3,850. Quite a feat, considering this list only features America's fastest-growing private companies. Apex isn't just maintaining its position out of sheer luck. Revenue shot up by 67% over...
Continue Reading
Legal Maneuver Against Lincoln Educational Services Here we go again—another day, another lawsuit. The recent flap with Lincoln Educational Services Corporation (NASDAQ: LINC) is as classic as any market rug pull. Stepping into the spotlight, Wolf Haldenstein Adler Freeman & Herz LLP—a courtroom icon since 1888—has announced a class action lawsuit against Lincoln....
Continue Reading
Newmark Banks on Steamboat's Future Diving headfirst into the deep end, Newmark (NASDAQ: NMRK) just roped in a colossal $482.5 million loan for a new gem in Steamboat Springs, Colorado. Inking a deal of this magnitude ain't your everyday rinse-and-repeat; it's a bold move that speaks volumes about where the big shots think value's heading. The Financial Fuel: GoldenTree...
Continue Reading
Greasezilla is shaking up the world of waste management, folks. With municipal sewer systems clogged by fats, oils, and grease, Greasezilla's no-nonsense approach is a breath of fresh air. They've just fired up their new regional hub in Ashland, Virginia, taking another hefty step towards easing this burden on municipalities. This ain't small potatoes—this national...
Continue Reading
The cosmos are back on the show menu at Florida Southern College, folks. Let's dig into what that means for history buffs and star gazers alike. We're talking about the big reopening of the college's Frank Lloyd Wright designed Planetarium—a space that's been gathering dust for far too long. Dive in with me to see why this is more than just a coat of paint on an old...
Continue Reading
Infrared Imaging: The Backbone of Future Tech Kinda wild how infrared imaging's become a hot topic in tech circles. With the market expected to jump from USD 9.2 billion in 2026 to a hefty USD 12.6 billion by 2031, averaging a 6.4% growth rate, there's plenty to chew on. Even if you ain't the analytical type, it ain't hard to spot where the money's flowing. Infrared's...
Continue Reading
Something's Buzzing at the Big Board Walk over to Wall Street on September 23rd, and guess what you get? A lot more than just stock tickers blinking away. First Lady Melania Trump’s stealing the show at the New York Stock Exchange to kick off the inaugural IMPERIA Summit. She’s there to sound the opening bell and lead the charge in a summit that's focused on the...
Continue Reading
Top 5 Most Recently Viewed Articles
First Command Financial Services Inc. made a bold move back in 2024 by bringing John Woerner onto its board of directors. This isn't just a random hire; it’s a strategic step aimed at solidifying the firm's promise of top-tier financial guidance for military families. In a sector where trust is currency, this addition signals serious intent. John Woerner's Impressive...
Continue Reading
Allarity Therapeutics Announces Phase 2 Trial Enrollment Allarity Therapeutics, Inc. (NASDAQ: ALLR), a clinical-stage biopharmaceutical company focused on personalized cancer treatments, is excited to announce the commencement of patient enrollment for its new Phase 2 clinical trial protocol targeting advanced ovarian cancer. This trial aims to advance stenoparib, a novel...
Continue Reading
Quarterly Results Overview Peabody, a leading coal producer, recently shared insights into its performance over the third quarter. Despite experiencing a net income attributable to common stockholders of $(70.1) million, including $54.0 million in costs related to a terminated acquisition, the company showcased a formidable operational resilience. This translated into an...
Continue Reading
Fast Casual Restaurants Market Overview The fast casual restaurants market is undergoing a remarkable transformation, with projections estimating growth of USD 302.5 billion from 2024 to 2028. This growth is attributed primarily to the increasing demand for menu innovation and customization in the dining experience. As consumers seek more personalized and healthier food...
Continue Reading
ASSYST Strengthens Commitment to National Security ASSYST has recently expanded its valuable Homeland & National Security Practice. This enhancement is aimed explicitly at addressing the intricate demands of federal agencies tasked with national resilience, emergency response, border protection, and cybersecurity. This growth not only amplifies ASSYST's service offerings...
Continue Reading